American Association for Cancer Research Release: PV-10 Immunology Data Presented by Moffit Cancer Center Researchers at the Provectus Pharmaceuticals Inc. Annual Meeting
4/9/2013 6:12:42 AM
More...
|
Data on Provectus Pharmaceuticals Inc.'s PV-10 to be Presented at the HemOnc Today – Melanoma and Cutaneous Malignancies Conference on March 22, 2013
3/20/2013 9:44:25 AM
More...
|
Provectus Pharmaceuticals Inc. Shares Are Trading on the OTCQB
1/25/2013 9:07:28 AM
More...
|
Provectus Pharmaceuticals Inc. Launches Free Mobile Investor Relations Application
1/24/2013 9:43:22 AM
More...
|
Provectus Pharmaceuticals Inc. to Present Data on PV-10 at the American Association for Cancer Research Annual Meeting in April 2013
1/23/2013 9:37:41 AM
More...
|
Provectus Pharmaceuticals Inc. Announces H. Lee Moffitt Cancer Center & Research Institute Initiates Phase 1 Study of PV-10 to Elucidate Bystander Effect
1/8/2013 9:45:54 AM
More...
|
Provectus Pharmaceuticals Inc. Presents Nonclinical Data on Antitumor Immune Response to PV-10 Immuno-Chemoablation
10/29/2012 6:33:14 AM
More...
|
Provectus Pharmaceuticals Inc. Terminates Proposed Convertible Preferred Stock Offering
10/18/2012 9:47:32 AM
More...
|
Provectus Pharmaceuticals Inc. Presents Final Phase 2 Melanoma Data at ESMO 2012
10/2/2012 9:52:25 AM
More...
|
Provectus Pharmaceuticals Inc.'s Patent Application Published for Combining Local and Systemic Therapies for Enhanced Treatment of Cancer
9/28/2012 10:36:48 AM
More...
|
|